Detailed Mechanism Funding and Narrative

Years of mechanism: 2012 2013 2014 2015 2016 2017 2018 2019 2020

Details for Mechanism ID: 13583
Country/Region: Mozambique
Year: 2016
Main Partner: Columbia University
Main Partner Program: Mailman School of Public Health
Organizational Type: University
Funding Agency: HHS/CDC
Total Funding: $18,640,588 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $2,204,541
Care: TB/HIV (HVTB) $498,079
Care: Pediatric Care and Support (PDCS) $395,311
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $3,333,881
Testing: HIV Testing and Counseling (HVCT) $1,216,110
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $2,555,292
Treatment: Adult Treatment (HTXS) $6,737,127
Treatment: Pediatric Treatment (PDTX) $1,700,247
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
GEND_GBV By PEP service provision (related to sexual violence services provided) 2017 244
GEND_GBV By type of service: Physical and/or Emotional Violence (Other Post-GBV Care) 2017 966
GEND_GBV By type of service: Sexual Violence (Post-Rape Care) 2017 329
GEND_GBV Number of people receiving post-GBV care 2017 1,279
HRH_PRE By Graduates: Nurses 2017 70
HRH_PRE Number of new HCW who graduated from a pre-service training institution or program as a result of PEPFAR-supported strengthening efforts, within the reporting period, by select cadre 2017 70
HRH_PRE Sum of Graduates disaggregates 2017 70
HTS_TST Age/sex: <1 2017 358
HTS_TST Age/sex: 1-9 2017 1,444
HTS_TST Age/sex: 10-14 Male 2017 1,755
HTS_TST Age/sex: 15-19 Male 2017 2,317
HTS_TST Age/sex: 20-24 Male 2017 2,272
HTS_TST Age/sex: 25-49 Male 2017 4,077
HTS_TST Age/sex: 50+ Male 2017 858
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 18,150
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Female 2017 42,920
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 10,083
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: <15 Male 2017 43,812
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 196,727
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Female 2017 367,102
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 23,325
HTS_TST Aggregated Age/sex - USE WITH HQ PERMISSION ONLY: 15+ Male 2017 96,218
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 248,285
HTS_TST Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2017 550,027
HTS_TST Service Delivery Point (Community): Index testing 2017 7,615
HTS_TST Service Delivery Point (Facility): Index testing 2017 29,309
HTS_TST Service Delivery Point (Facility): Other PITC 2017 6,527
HTS_TST Service Delivery Point (Facility): Other PITC 2017 18,175
HTS_TST Service Delivery Point (Facility): Outpatient 2017 89,444
HTS_TST Service Delivery Point (Facility): Outpatient 2017 150,729
HTS_TST Service Delivery Point (Facility): Pediatric 2017 396
HTS_TST Service Delivery Point (Facility): Pediatric 2017 1,289
HTS_TST Service Delivery Point (Facility): PMTCT 2017 127,016
HTS_TST Service Delivery Point (Facility): PMTCT 2017 227,124
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 1,730
HTS_TST Service Delivery Point (Facility): TB Clinics 2017 3,560
HTS_TST Service Delivery Point (Facility): VCT 2017 23,172
HTS_TST Service Delivery Point (Facility): VCT 2017 57,196
HTS_TST Service Delivery Point (Facility): VMMC 2017 55,030
HTS_TST Sum of Age/Sex disaggregates 2017 11,279
HTS_TST Sum of Aggregated Age/Sex <15 2017 28,233
HTS_TST Sum of Aggregated Age/Sex <15 2017 86,732
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 220,052
HTS_TST Sum of Aggregated Age/Sex 15+ 2017 463,320
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 248,285
HTS_TST Sum of Aggregated Age/Sex disaggregates 2017 550,052
HTS_TST_POS Test Result by Age and Sex: Positive: 10-14 Male 2017 1
HTS_TST_POS Test Result by Age and Sex: Positive: 15-19 Male 2017 9
HTS_TST_POS Test Result by Age and Sex: Positive: 20-24 Male 2017 24
HTS_TST_POS Test Result by Age and Sex: Positive: 25-49 Male 2017 104
HTS_TST_POS Test Result by Age and Sex: Positive: 50+ Male 2017 21
HTS_TST_POS Test Result by Age: Positive: 1-9 2017 4
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 357
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Female 2017 1,654
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 266
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive <15 Male 2017 1,343
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 7,289
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Female 2017 28,441
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 2,609
HTS_TST_POS Test Result by Aggregated Age and Sex: Positive 15+ Male 2017 12,860
PMTCT_ART Already on ART at beginning of current pregnancy 2017 1,479
PMTCT_ART Already on ART at beginning of current pregnancy 2017 4,870
PMTCT_ART New on ART 2017 2,213
PMTCT_ART New on ART 2017 7,304
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 128,073
PMTCT_ART Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 230,490
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 2,059
PMTCT_EID By infants who received a virologic test within 2 months of birth 2017 7,711
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 925
PMTCT_EID By infants who received their first virologic HIV test between 2 and 12 months of age 2017 3,463
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 76
PMTCT_EID Number of infants with a positive virological test result within 12 months of birth 2017 278
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 103
PMTCT_EID Number of infants with a positive virological test result within 2 months of birth 2017 382
PMTCT_EID Sum of Infant Age disaggregates 2017 2,984
PMTCT_EID Sum of Infant Age disaggregates 2017 11,174
PMTCT_STAT By: Known positives at entry 2017 1,492
PMTCT_STAT By: Known positives at entry 2017 4,917
PMTCT_STAT By: Number of new positives identified 2017 2,237
PMTCT_STAT By: Number of new positives identified 2017 7,380
PMTCT_STAT Number of new ANC and L&D clients 2017 129,370
PMTCT_STAT Number of new ANC and L&D clients 2017 232,821
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 128,073
PMTCT_STAT Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2017 230,490
PMTCT_STAT Sum of Positives Status disaggregates 2017 3,729
PMTCT_STAT Sum of Positives Status disaggregates 2017 12,297
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 772
TB_ART Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 2,529
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 415
TB_ART Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2017 1,365
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 1,184
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status during TB treatment during the reporting period 2017 3,892
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 1,184
TB_ART The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2017 3,892
TB_SCREENDX Screen Result: Screened Positive for TB 2017 9,525
TB_SCREENDX Screen Results: Screened Positive for TB 2017 2,574
TB_SCREENDX Screened for TB by Age/Sex: <15 Female 2017 1,478
TB_SCREENDX Screened for TB by Age/Sex: <15 Male 2017 1,478
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 19,026
TB_SCREENDX Screened for TB by Age/Sex: 15+ Female 2017 70,803
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 10,243
TB_SCREENDX Screened for TB by Age/Sex: 15+ Male 2017 38,128
TB_SCREENDX Screened for TB by Age/Sex:<15 Female 2017 5,122
TB_SCREENDX Screened for TB by Age/Sex:<15 Male 2017 5,122
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 32,208
TB_SCREENDX The number of PLHIV who were screened for TB symptoms at the last clinical visit at a HIV facility during the reporting period 2017 119,083
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 2,822
TB_STAT Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 6,257
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 1,520
TB_STAT Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2017 3,374
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 4,341
TB_STAT Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2017 9,630
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 4,341
TB_STAT Total number of registered new and relapsed TB cases, during the reporting period 2017 9,630
TX_CURR Age/Sex: <1 2017 604
TX_CURR Age/Sex: <1 2017 136
TX_CURR Aggregated Age/Sex: <15 Female 2017 4,620
TX_CURR Aggregated Age/Sex: <15 Female 2017 1,263
TX_CURR Aggregated Age/Sex: <15 Male 2017 1,263
TX_CURR Aggregated Age/Sex: <15 Male 2017 4,620
TX_CURR Aggregated Age/Sex: 15+ Female 2017 59,768
TX_CURR Aggregated Age/Sex: 15+ Female 2017 15,039
TX_CURR Aggregated Age/Sex: 15+ Male 2017 32,190
TX_CURR Aggregated Age/Sex: 15+ Male 2017 8,095
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 25,642
TX_CURR Number of adults and children receiving antiretroviral therapy (ART) 2017 101,130
TX_CURR Sum of Aggregated Age/Sex <15 2017 9,240
TX_CURR Sum of Aggregated Age/Sex <15 2017 2,526
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 91,958
TX_CURR Sum of Aggregated Age/Sex 15+ 2017 23,134
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 101,198
TX_CURR Sum of Aggregated Age/Sex disaggregates 2017 25,660
TX_NEW Aggregated Grouping by Age: <1 2017 136
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 474
TX_NEW Aggregated Grouping by Age/Sex: <15 Female 2017 2,375
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 3,236
TX_NEW Aggregated Grouping by Age/Sex: <15 Male 2017 21,173
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 474
TX_NEW Aggregated Grouping by Age/Sex: 15+ Female 2017 2,375
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 1,742
TX_NEW Aggregated Grouping by Age/Sex: 15+ Male 2017 11,386
TX_NEW By Age/Sex: <1 2017 604
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 5,912
TX_NEW Number of adults and children newly enrolled on antiretroviral therapy (ART) 2017 37,251
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 5,926
TX_NEW Sum of Aggregated Age/Sex disaggregates 2017 37,309
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 10,662
TX_PVLS Number of adult and pediatric ART patients with a viral load result documented in the patient medical record and /or laboratory records in the past 12 months 2017 33,419
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 7,994
TX_PVLS Number of adults and pediatric patients on ART with suppressed viral load results (<1,000 copies/ml) documented in the medical records and /or supporting laboratory results within the past 12 months 2017 25,067
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 579
TX_PVLS Numerator Aggregated Age/Sex: <15 Female 2017 2,016
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 4,456
TX_PVLS Numerator Aggregated Age/Sex: <15 Male 2017 13,714
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 579
TX_PVLS Numerator Aggregated Age/Sex: 15+ Female 2017 2,016
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 2,396
TX_PVLS Numerator Aggregated Age/Sex: 15+ Male 2017 7,386
TX_PVLS Numerator: Indication: Routine 2017 944
TX_PVLS Numerator: Indication: Routine 2017 4,861
TX_PVLS Numerator: Indication: Targeted 2017 7,050
TX_PVLS Numerator: Indication: Targeted 2017 20,206
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 771
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Female 2017 2,679
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 771
TX_PVLS_den Denominator Aggregated Age/Sex: <15 Male 2017 2,679
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 5,943
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Female 2017 18,281
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 3,200
TX_PVLS_den Denominator Aggregated Age/Sex: 15+ Male 2017 9,841
TX_PVLS_den Denominator: Indication: Routine 2017 1,254
TX_PVLS_den Denominator: Indication: Routine 2017 6,480
TX_PVLS_den Denominator: Indication: Targeted 2017 9,408
TX_PVLS_den Denominator: Indication: Targeted 2017 26,939
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 483
TX_RET Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,234
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 4,258
TX_RET Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 21,428
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 483
TX_RET Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 1,234
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 2,293
TX_RET Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2017 11,537
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 7,504
TX_RET Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2017 35,365
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 10,725
TX_RET Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2017 46,475
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 688
TX_RET_den Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,610
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 6,085
TX_RET_den Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 28,164
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 688
TX_RET_den Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 1,610
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 3,275
TX_RET_den Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2017 15,164
VMMC_CIRC By Age: 10-14 2017 13,758
VMMC_CIRC By Age: 15-19 2017 16,509
VMMC_CIRC By Age: 20-24 2017 13,758
VMMC_CIRC By Age: 25-29 2017 8,255
VMMC_CIRC By Age: 30-49 2017 2,750
VMMC_CIRC By circumcision technique: Surgical VMMC 2017 55,030
VMMC_CIRC Number of males circumcised as part of the voluntary medical male circumcision (VMMC) for HIV prevention program within the reporting period 2017 55,030
VMMC_CIRC Sum of age disaggregates (FY15-Current) 2017 55,030
VMMC_CIRC Sum of age disaggregates (Prior to FY15) 2017 44,025
Cross Cutting Budget Categories and Known Amounts Total: $524,226
Gender: Gender Based Violence (GBV) $524,226
Post GBV Care
Implementation
Capacity building
Monitoring and Evaluation